BACKGROUND Systemic glucocorticoids reduce the incidence of bronchopulmonary dysplasia among extremely preterm infants, but they may compromise brain development. The effects of inhaled glucocorticoids on outcomes in these infants are unclear. METHODS We randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to early (within 24 hours after birth) inhaled budesonide or placebo until they no longer required oxygen and positive-pressure support or until they reached a postmenstrual age of 32 weeks 0 days. The primary outcome was death or bronchopulmonary dysplasia, confirmed by means of standardized oxygen-saturation monitoring, at a postmenstrual age of 36 weeks. RESULTS A total of 175 of 437 infants assigned to budesonide for whom adequate data were available (40.0%), as compared with 194 of 419 infants assigned to placebo for whom adequate data were available (46.3%), died or had bronchopulmonary dysplasia (relative risk, stratified according to gestational age, 0.86; 95% confidence interval [CI], 0.75 to 1.00; P = 0.05). The incidence of bronchopulmonary dysplasia was 27.8% in the budesonide group versus 38.0% in the placebo group (relative risk, stratified according to gestational age, 0.74; 95% CI, 0.60 to 0.91; P = 0.004); death occurred in 16.9% and 13.6% of the patients, respectively (relative risk, stratified according to gestational age, 1.24; 95% CI, 0.91 to 1.69; P = 0.17). The proportion of infants who required surgical closure of a patent ductus arteriosus was lower in the budesonide group than in the placebo group (relative risk, stratified according to gestational age, 0.55; 95% CI, 0.36 to 0.83; P = 0.004), as was the proportion of infants who required reintubation (relative risk, stratified according to gestational age, 0.58; 95% CI, 0.35 to 0.96; P = 0.03). Rates of other neonatal illnesses and adverse events were similar in the two groups. CONCLUSIONS Among extremely preterm infants, the incidence of bronchopulmonary dysplasia was lower among those who received early inhaled budesonide than among those who received placebo, but the advantage may have been gained at the expense of increased mortality.

Early inhaled budesonide for the prevention of bronchopulmonary dysplasia

GHIRRI, PAOLO;
2015-01-01

Abstract

BACKGROUND Systemic glucocorticoids reduce the incidence of bronchopulmonary dysplasia among extremely preterm infants, but they may compromise brain development. The effects of inhaled glucocorticoids on outcomes in these infants are unclear. METHODS We randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to early (within 24 hours after birth) inhaled budesonide or placebo until they no longer required oxygen and positive-pressure support or until they reached a postmenstrual age of 32 weeks 0 days. The primary outcome was death or bronchopulmonary dysplasia, confirmed by means of standardized oxygen-saturation monitoring, at a postmenstrual age of 36 weeks. RESULTS A total of 175 of 437 infants assigned to budesonide for whom adequate data were available (40.0%), as compared with 194 of 419 infants assigned to placebo for whom adequate data were available (46.3%), died or had bronchopulmonary dysplasia (relative risk, stratified according to gestational age, 0.86; 95% confidence interval [CI], 0.75 to 1.00; P = 0.05). The incidence of bronchopulmonary dysplasia was 27.8% in the budesonide group versus 38.0% in the placebo group (relative risk, stratified according to gestational age, 0.74; 95% CI, 0.60 to 0.91; P = 0.004); death occurred in 16.9% and 13.6% of the patients, respectively (relative risk, stratified according to gestational age, 1.24; 95% CI, 0.91 to 1.69; P = 0.17). The proportion of infants who required surgical closure of a patent ductus arteriosus was lower in the budesonide group than in the placebo group (relative risk, stratified according to gestational age, 0.55; 95% CI, 0.36 to 0.83; P = 0.004), as was the proportion of infants who required reintubation (relative risk, stratified according to gestational age, 0.58; 95% CI, 0.35 to 0.96; P = 0.03). Rates of other neonatal illnesses and adverse events were similar in the two groups. CONCLUSIONS Among extremely preterm infants, the incidence of bronchopulmonary dysplasia was lower among those who received early inhaled budesonide than among those who received placebo, but the advantage may have been gained at the expense of increased mortality.
2015
Bassler, Dirk; Plavka, Richard; Shinwell, Eric S.; Hallman, Mikko; Jarreau, Pierre Henri; Carnielli, Virgilio; Van Den Anker, Johannes N.; Meisner, Christoph; Engel, Corinna; Schwab, Matthias; Halliday, Henry L.; Poets, Christian F; NEUROSIS Trial Group Plavka, R; Seipolt, B; Jarreau, Ph; Richardson, J; Dadoun, S; Bassler, D; Poets, Cf; Kreutzer, K; Koch, A; Schneider, B; Koluch, Ad; Dort, J; Huml, P; Matas, M; Dortová, E; Mockova, A; Šusterová, L; Pennaforte, T; Hallman, M; Aikio, O; Vikeväinen, R; Mahlman, M; Shinwell, Es; Rimon, Of; Reicher, Aj; Rozin, I; Levin, M; Kari, M; Andersson, S; Ketola, I; Tammela, O; Carnielli, V; Nobile, S; Stein, A; Felderhoff Müser, U; Poláčková, R; Juren, T; Kučera, M; Pöschl, J; Beedgen, B; Ronellenfitsch, S; Macko, J; Cerný, M; Kabisch, S; Bader, D; Bar Oz, B; Golzand, E; Yaari, M; Schiffmann, H; Schäfer, S; Bohnhorst, B; Ehlers, S; Küster, H; Lazer, N; De Beauregard, Vg; Haumont, D; Vlieghe, V; Johansson, Ab; van den Anker, J; Kornelisse, Rf; Tibboel, D; Litmanovitz, I; Arnon, S; Gancia, P; Dalmazzo, C; Pomero, G; Decaluwe, W; Metsvaht, T; Varendi, H; Schoberer, M; Trepels Kottek, S; Norbert, K; Saliba, E; Martano, C; Borgione, S; Menendez Castro, C; Rascher, W; Sankilampi, U; Malfilâtre, G; Ghirri, Paolo; Chiandetti, L; Bassler, D; Carnielli, V; Halliday, Hl; Hallman, M; Jarreau, Ph; Plavka, R; Poets, Cf; Schwab, M; Shinwell, Es; van den Anker, J; Aranda, J; Boyle, E; Roberts, R; Meisner, C; Engel, C.
File in questo prodotto:
File Dimensione Formato  
Ghirri_808811.pdf

accesso aperto

Tipologia: Versione finale editoriale
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 449.07 kB
Formato Adobe PDF
449.07 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/808811
Citazioni
  • ???jsp.display-item.citation.pmc??? 60
  • Scopus 197
  • ???jsp.display-item.citation.isi??? 171
social impact